XBiotech announced today that that Dirk Arnold, international specialist in gastrointestinal cancers, has joined the Company’s Scientific Advisory Board (SAB).
Arnold will work with XBiotech to help navigate clinical development and communicate the findings for the company’s lead product candidate in advanced colorectal cancer.
Arnold’s main research interests include the treatment of GI cancers with a focus on targeted and immunotherapies, among others.
Importantly, his special interest in clinical research methodologies and benefit evaluation are relevant to one of XBiotech’s lead oncology programs, which has involved the development of a novel measure of clinical efficacy in advanced cancer patients.
Arnold is a member of the following organisations:
- German Cancer Society
- German Society of Haematology and Medical Oncology
- Executive Board of the European Society for Medical Oncology and European Cancer Organisation
- Chair of Colorectal Cancer Study Group of the German Society of Clinical Oncology
- American Society of Clinical Oncology
- Task Force Colorectal Cancer of the European Organization for Research and Treatment of Cancer, GI study group.
He is currently Director of the Insituto CUF de Oncologia in Lisbon, Portugal.
